NDAINJECTIONINJECTABLE
Approved
Sep 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ERYTHROCIN (erythromycin lactobionate) by Pfizer is clinical pharmacology erythromycin diffuses readily into most body fluids. Approved for penicillin-allergic patients, the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below, the severity of the infection requires immediate high serum levels of erythromycin. First approved in 1986.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ERYTHROCIN (erythromycin lactobionate) is an intravenous macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It is indicated for serious infections caused by susceptible gram-positive and gram-negative bacteria, particularly in penicillin-allergic patients requiring immediate high serum levels. The drug provides rapid IV delivery with peak serum levels of 10 mcg/mL achieved within 1 hour of infusion.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%) indicates team restructuring likely and reduced commercial investment expected.
Mechanism of Action
CLINICAL PHARMACOLOGY Erythromycin diffuses readily into most body fluids. In the absence of meningeal inflammation, low concentrations are normally achieved in the spinal fluid but the passage of the drug across the blood-brain barrier increases in meningitis. Erythromycin crosses the placental…
Worked on ERYTHROCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.